Bora Pharmaceuticals (保瑞藥業) announced on May 18, 2026, the signing of a landmark 10+2 year manufacturing agreement valued in the tens of billions of New Taiwan Dollars with a top 20 global biopharmaceutical corporation. Under this contract, Bora will leverage its global network to deliver one-stop CDMO solutions spanning development, manufacturing, packaging, and analytical services.
Read more
